Register
ABILITY-3 shows higher rates of maintenance remission with adalimumab |
Journal Updates
eMediNexus Coverage from: 
ABILITY-3 shows higher rates of maintenance remission with adalimumab

0 Read Comments                

In patients with active non-radiographic axial spondyloarthritis who achieved sustained remission with adalimumab, continued treatment with adalimumab was associated with significantly fewer patients flaring compared with treatment withdrawal. These findings from the ABILITY-3 trial were published online June 28, 2018 in The Lancet.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now